Kane presents revyve data at wound care conference

• Kane Biotech presented clinical case study data at the SAWC Spring Conference on April 16, 2026.
• Data demonstrates efficacy of revyve® technology in treating chronic, non-healing wounds including Venous Leg Ulcers (VLU) and deep tunneling wounds.
• Key metrics include 85% wound size reduction at 33 weeks for VLU patients and 90% volume reduction for deep tunneling wounds within seven months.
• Mechanistic studies show the technology normalizes chronic wound pH from 8.0 to 6.8 within four weeks, correlating with accelerated healing.
• Regulatory status remains strong: revyve Antimicrobial Wound Gel and Spray are FDA 510(k) cleared and Health Canada approved; Cleanser is also FDA 510(k) cleared.
• This follows a series of commercial restart announcements in February 2026, including distribution agreements with Marathon Medical Corporation for federal procurement channels (VA, DoD, IHS).

• The news is positive but incremental relative to the company's current stage; clinical validation was anticipated following previous conference presentations in late 2025 and early 2026.
• It reinforces the commercial strategy announced in February 2026 rather than introducing a new revenue driver or partnership.
• No financial metrics (revenue, cash flow) were disclosed in this release; Q3 2025 results showed revenue of only $8,499 despite regulatory clearance.
• The data supports the "scientific credibility" pillar but does not yet prove commercial scalability or significant top-line growth.
• Given the company's history of revenue collapse (from $1.28M to $8k), clinical success alone is insufficient to alter the investment thesis without evidence of sales traction.

• Company: Kane Biotech Inc., focused on antimicrobial wound care solutions.
• Flagship Product: revyve® Antimicrobial Wound Gel, Spray, and Cleanser utilizing thermoreversible technology to normalize wound pH and eradicate biofilms.
• Development Stage: Commercialization phase; products are FDA 510(k) cleared (US) and Health Canada approved.
• Technology: Thermo-reversible gel transitions from liquid to gel at body temperature for atraumatic removal; claims rapid antimicrobial activity against antibiotic-tolerant biofilms.
• Market Focus: Chronic wounds, diabetic foot ulcers, burns, and venous leg ulcers in North America (US/Canada).